![](https://cdn.sanity.io/images/0vv8moc6/drugtopics/f0010ced1dcfa5b0212def1338f2597d996a85a9-5472x3648.jpg?fit=crop&auto=format)
Pfizer Advances Oral GLP-1 Development as the Race for Second-Gen Obesity Therapies Continues
Pfizer will advance their development of danuglipron, a once-daily oral glucagon-like peptide 1 (GLP-1) receptor agonist, the company announced in a news release.1 The decision is based on results of an ongoing pharmacokinetic study (NCT06163758) which …